Clinical Pharmacology & Therapeutics · 2001 · 116 citations · 15 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPain ManagementPain MedicineAnalgesiaAnalgesic PharmacologyGastrointestinal PharmacologyGastrointestinal TransitOpioid AnalgesicsOpioid PharmacologyClinical Pharmacology EvidenceGastrointestinal Transit ControlHydrogen Breath TestingOpioid Antagonist TherapyPeripheral Opioid MechanismsPeripherally Acting Opioid Receptor AntagonistsPostoperative Opioid Analgesia
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo. Analgesia and pupil constriction were measured. Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002). We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
15
Opioid-induced Delay in Gastric Emptying
Damian B. Murphy, J. A. Sutton, L. F. Prescott et al. · Anesthesiology · 1997 · 272 citations · Full text
Chun‐Su Yuan, Joseph Foss, Michael O’Connor et al. · Clinical Pharmacology & Therapeutics · 1996 · 215 citations
Oral naloxone reverses opioid-associated constipation
U. Schmidt, Michael Hartmann, R. Kath et al. · Pain · 2000 · 203 citations